BJCM
Blue Jay Capital Management Portfolio holdings
AUM
$147M
This Quarter Return
+9.48%
1 Year Return
+64.18%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$297M
AUM Growth
+$297M
(+17%)
Cap. Flow
+$48.6M
Cap. Flow
% of AUM
16.38%
Top 10 Holdings %
Top 10 Hldgs %
53.44%
Holding
31
New
13
Increased
4
Reduced
6
Closed
8
Top Buys
| 1 |
SHPG
Shire pic
SHPG
|
$18.9M |
| 2 |
ENDP
Endo International plc
ENDP
|
$15.6M |
| 3 |
BXLT
BAXALTA INC COM STK (DE)
BXLT
|
$15M |
| 4 |
NVRO
NEVRO CORP.
NVRO
|
$12.8M |
| 5 |
IPXL
Impax Laboratories, Inc.
IPXL
|
$12.6M |
Top Sells
| 1 |
Incyte
INCY
|
$16M |
| 2 |
BioMarin Pharmaceuticals
BMRN
|
$14.7M |
| 3 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$14.1M |
| 4 |
NUVA
NuVasive, Inc.
NUVA
|
$13.7M |
| 5 |
WCG
Wellcare Health Plans, Inc.
WCG
|
$12.9M |
Sector Composition
| 1 | Healthcare | 82.94% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Intuitive Surgical
ISRG
$170B
| $20.2M | 6.81% | 37,000 +7,000 | +23% | +$3.82M |
|
2
Edwards Lifesciences
EW
$47.8B
| $19.9M | 6.72% | 252,500 +101,816 | +68% | +$8.04M |
|
|
SHPG
3
DELISTED
Shire pic
SHPG
| $18.9M | 6.36% | +92,030 | New | +$18.9M |
|
4
Biogen
BIIB
$19.4B
| $17.8M | 6.01% | 58,161 +15,661 | +37% | +$4.8M |
|
|
ENDP
5
DELISTED
Endo International plc
ENDP
| $15.6M | 5.26% | +255,080 | New | +$15.6M |
|
|
BXLT
6
DELISTED
BAXALTA INC COM STK (DE)
BXLT
| $15M | 5.07% | +385,000 | New | +$15M |
|
|
CERN
7
DELISTED
Cerner Corp
CERN
| $13M | 4.39% | 216,339 +36,339 | +20% | +$2.19M |
|
|
NVRO
8
DELISTED
NEVRO CORP.
NVRO
| $12.8M | 4.32% | +190,000 | New | +$12.8M |
|
|
IPXL
9
DELISTED
Impax Laboratories, Inc.
IPXL
| $12.6M | 4.25% | +295,000 | New | +$12.6M |
|
10
Hologic
HOLX
$14.9B
| $12.6M | 4.25% | +325,747 | New | +$12.6M |
|
11
Quest Diagnostics
DGX
$20.3B
| $12.5M | 4.2% | +175,160 | New | +$12.5M |
|
12
Cooper Companies
COO
$13.4B
| $12.1M | 4.07% | 90,000 -30,000 | -25% | -$4.03M |
|
13
Agilent Technologies
A
$35.7B
| $11.9M | 4.02% | +285,000 | New | +$11.9M |
|
14
Bristol-Myers Squibb
BMY
$96B
| $11.3M | 3.81% | +164,518 | New | +$11.3M |
|
15
Neurocrine Biosciences
NBIX
$13.8B
| $11.3M | 3.81% | +200,060 | New | +$11.3M |
|
|
WMGI
16
DELISTED
Wright Medical Group Inc
WMGI
| $10.9M | 3.67% | 450,000 -115,000 | -20% | -$2.78M |
|
|
CPHD
17
DELISTED
Cepheid Inc
CPHD
| $10.6M | 3.57% | 290,000 -18,909 | -6% | -$691K |
|
18
Vertex Pharmaceuticals
VRTX
$100B
| $10.1M | 3.39% | 80,020 -58,118 | -42% | -$7.31M |
|
|
QGENF
19
DELISTED
QIAGEN NV
QGENF
| $9.95M | 3.36% | 360,000 -65,000 | -15% | -$1.8M |
|
20
Assertio
ASRT
$80.4M
| $9.7M | 3.27% | +535,000 | New | +$9.7M |
|
21
Perrigo
PRGO
$3.27B
| $9.49M | 3.2% | 65,600 -49,400 | -43% | -$7.15M |
|
|
STJ
22
DELISTED
St Jude Medical
STJ
| $9.42M | 3.18% | +152,500 | New | +$9.42M |
|
23
Masimo
MASI
$7.59B
| $8.93M | 3.01% | +215,000 | New | +$8.93M |
|
24
Brookdale Senior Living
BKD
$1.83B
| – | – | -560,220 | Closed | -$12.9M |
|
|
25
BioMarin Pharmaceuticals
BMRN
$11.2B
| – | – | -139,164 | Closed | -$14.7M |
|